Eptifibatide
Eptifibatide is an FDA-approved glycoprotein IIb in the Platelet Glycoprotein Inhibitor class. Eptifibatide contains a KGD sequence modelled on the RGD motif that fibrinogen uses to engage platelet glycoprotein IIb/IIIa. By occupying that receptor reversibly it prevents fibrinogen and von Willebrand factor cross-linking of platelets, blocking the final common step of platelet aggregation.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 832 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- intravenous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Cyclic heptapeptide platelet aggregation inhibitor approved for acute coronary syndrome and for patients undergoing percutaneous coronary intervention.
Peptide Library's Eptifibatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- intravenous
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Eptifibatide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C35H49N11O9S2 |
|---|---|
| Molecular weight | 832 g/mol |
| PubChem CID | 448812 |
| FDA UNII | NA8320J834 |
| ChEMBL | CHEMBL1174 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Eptifibatide contains a KGD sequence modelled on the RGD motif that fibrinogen uses to engage platelet glycoprotein IIb/IIIa. By occupying that receptor reversibly it prevents fibrinogen and von Willebrand factor cross-linking of platelets, blocking the final common step of platelet aggregation. Its short half-life means platelet function recovers within hours of stopping the infusion.
Studies
- Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial
- Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
- Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy
- Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer
- Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study)
Regulatory & research status
Eptifibatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Eptifibatide: frequently asked questions
What is Eptifibatide?
Cyclic heptapeptide platelet aggregation inhibitor approved for acute coronary syndrome and for patients undergoing percutaneous coronary intervention.
How does Eptifibatide work?
Eptifibatide contains a KGD sequence modelled on the RGD motif that fibrinogen uses to engage platelet glycoprotein IIb/IIIa. By occupying that receptor reversibly it prevents fibrinogen and von Willebrand factor cross-linking of platelets, blocking the final common step of platelet aggregation.
Is Eptifibatide FDA approved?
Yes. Eptifibatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Eptifibatide?
Compounds most often compared with Eptifibatide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial — Neurology, 2025External reference
- Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke — N Engl J Med, 2024External reference
- Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy — Circulation, 2004External reference
- Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer — Am J Ther, 2016External reference
- Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study) — Am J Cardiol, 2005External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Eptifibatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Eptifibatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →